Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An update from Hansa Biopharma AB ( (SE:HNSA) ) is now available.
Hansa Biopharma will publish its interim report for the first quarter of 2026 on 23 April and hold a conference call the same day, hosted by its top executives, to review financial results and provide a business and pipeline update. The English-language webcast and accompanying slides will be accessible through the company’s website, underlining its efforts to keep investors and other stakeholders informed about the progress of its immunomodulatory therapy portfolio and broader corporate strategy.
The call, led by the CEO, CFO, CMO and U.S. President and COO, signals continued emphasis on transparency around both commercial performance and clinical development, including assets such as imlifidase and next-generation candidates. By offering global dial-in options and an online webcast, Hansa aims to engage its international shareholder base and reinforce its positioning as a growing player in treatments for transplantation, gene therapy and autoimmune diseases.
The most recent analyst rating on (SE:HNSA) stock is a Hold with a SEK31.00 price target. To see the full list of analyst forecasts on Hansa Biopharma AB stock, see the SE:HNSA Stock Forecast page.
More about Hansa Biopharma AB
Hansa Biopharma AB is a commercial-stage biopharmaceutical company focused on developing and commercializing novel immunomodulatory therapies for acute and complex immune disorders. Built on a proprietary IgG-cleaving enzyme technology platform, its portfolio includes imlifidase, a first-in-class therapy enabling kidney transplantation in highly sensitized patients, and HNSA-5487, a next-generation molecule being developed for Guillain-Barré Syndrome, with operations in Europe and the U.S. and a listing on Nasdaq Stockholm under the ticker HNSA.
Average Trading Volume: 365,200
Technical Sentiment Signal: Strong Sell
Current Market Cap: SEK3.03B
For detailed information about HNSA stock, go to TipRanks’ Stock Analysis page.